The FDA has approved a new freeze-dried formulation of Jynneos (smallpox and mpox vaccine, live, non-replicating).

The global outbreak of mpox in 2022–23 affected more than 100 countries and grabbed the attention of the scientific community. Research on mpox has intensified since.

An advisory panel on vaccines meets, carefully, in the shadow of a health secretary who has often criticized it.

A recent study has shown that one dose of Bavarian Nordic’s Jynneos vaccine was overall 58% effective at preventing mpox ...

Discover why BVNKF's vaccine innovations, growth catalysts, and compelling valuation after a 52% pullback make it a strong ...

The freeze-dried formulation provides flexibility with regard to storage and shelf life. The Food and Drug Administration (FDA) has approved a new freeze-dried formulation of Jynneos ® (smallpox ...

The formulation allows for greater stockpiling, with Bavarian Nordic already working with the US government to add to vaccine ...

China on Thursday reported an outbreak of monkeypox virus, specifically the Ib sub-branch, with four associated cases. The ...

A new report from GlobalData has raised concerns over the effectiveness of mpox vaccines for people living with HIV. Findings ...

Marketed as Jynneos in the US, the vaccine currently exists in a liquid-frozen formulation. These products require a temperature-controlled supply chain that keeps them frozen between production ...